Eff ectiveness of bnt162b2 vaccine in adolescents during outbreak of sars-cov-2 delta variant infection, israel, 2021

Abstract

In Israel, the BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 was approved for use in adolescents in June 2021, shortly before an outbreak of B.1.617.2 (Delta) variant-dominant infection. We evaluated short-term vaccine eff ectiveness and found the vaccine to be highly eff ective among this population in this setting.